228 related articles for article (PubMed ID: 20170101)
21. Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
Sharma U; Cozier GE; Sturrock ED; Acharya KR
J Med Chem; 2020 May; 63(10):5488-5500. PubMed ID: 32337993
[TBL] [Abstract][Full Text] [Related]
22. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
[TBL] [Abstract][Full Text] [Related]
25. Vasopeptidase inhibition: a double-edged sword?
Campbell DJ
Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
[TBL] [Abstract][Full Text] [Related]
26. Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.
Lagunin AA; Gomazkov OA; Filimonov DA; Gureeva TA; Dilakyan EA; Kugaevskaya EV; Elisseeva YE; Solovyeva NI; Poroikov VV
J Med Chem; 2003 Jul; 46(15):3326-32. PubMed ID: 12852763
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
28. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE.
Ceconi C; Francolini G; Olivares A; Comini L; Bachetti T; Ferrari R
Eur J Pharmacol; 2007 Dec; 577(1-3):1-6. PubMed ID: 17716647
[TBL] [Abstract][Full Text] [Related]
30. An ACE structure.
Hooper NM; Turner AJ
Nat Struct Biol; 2003 Mar; 10(3):155-7. PubMed ID: 12605218
[No Abstract] [Full Text] [Related]
31. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Aulakh GK; Sodhi RK; Singh M
Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
[TBL] [Abstract][Full Text] [Related]
32. [Angiotensin converting enzyme inhibitors].
Sramko M; Remko M
Ceska Slov Farm; 2006 Jul; 55(4):160-7. PubMed ID: 16921734
[TBL] [Abstract][Full Text] [Related]
33. New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.
Sharma RK; Douglas RG; Louw S; Chibale K; Sturrock ED
Biol Chem; 2012 May; 393(6):485-93. PubMed ID: 22628311
[TBL] [Abstract][Full Text] [Related]
34. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates.
Bersanetti PA; Andrade MC; Casarini DE; Juliano MA; Nchinda AT; Sturrock ED; Juliano L; Carmona AK
Biochemistry; 2004 Dec; 43(50):15729-36. PubMed ID: 15595828
[TBL] [Abstract][Full Text] [Related]
35. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
[TBL] [Abstract][Full Text] [Related]
36. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
[TBL] [Abstract][Full Text] [Related]
37. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
[TBL] [Abstract][Full Text] [Related]
38. Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme.
Dalkas GA; Marchand D; Galleyrand JC; Martinez J; Spyroulias GA; Cordopatis P; Cavelier F
J Pept Sci; 2010 Feb; 16(2):91-7. PubMed ID: 20014331
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Natesh R; Schwager SL; Sturrock ED; Acharya KR
Nature; 2003 Jan; 421(6922):551-4. PubMed ID: 12540854
[TBL] [Abstract][Full Text] [Related]
40. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
